Skip to content

News & Events

Pierre Attali joins ORPHELIA Pharma Board Of Directors

25 June 2018

Paris and Lyon, June 25th 2018 – ORPHELIA Pharma, a French biopharmaceutical company dedicated to the development and marketing of paediatric drugs in the fields of oncology and neurology, announces today that Pierre Attali has joined its Board of Directors.

Pierre Attali, MD, will bring to ORPHELIA Pharma his expertise in clinical development, especially in oncology, acquired during a 30-year career in pharmaceutical and biotech companies. Dr. Attali was successively Head of Clinical Research Department, Licensing Director and General Manager at Synthelabo, Chief Operating Officer and Chief Medical Officer at Bioalliance / Onxeo, Chairman and Chief Executive Officer at Urogene. More recently, he joined Sensorion as Chief Medical Officer and Head R&D. He also founded and managed several biotech companies, such including OSMO, Molecular Engines Laboratories (MEL), and more recently Selexel.

Pierre Attali contributed to the development, registration and marketing of more than 10 novel  drugs and formulations, both in Europe and in the United States. He authored numerous peer-reviewed scientific publications and patents.

« We are particularly honoured to welcome Pierre at ORPHELIA Pharma » comments Gilles Alberici, Chairman of ORPHELIA Pharma. « His deep knowledge of drug development, especially in the oncology therapeutic area, will be invaluable to us ».

 « I am very pleased to join the Board of ORPHELIA Pharma » says Pierre Attali; « I personally know and appreciate the management team since many years. The culture of the company, aiming at improving patient’s care and focusing on paediatric medicines is paramount to my own personal values».

About ORPHELIA Pharma

Based in Paris and Lyon, ORPHELIA Pharma SAS is a French biopharmaceutical company dedicated to the development and marketing of oncology and neurology pediatric drugs. Its mission is to significantly improve essential medicines administered to children through the development of efficient, reliable and safe drugs with child-friendly formulations. ORPHELIA Pharma also leads innovative R&D projects through academic and industrial partnerships. Key investors include initiative OCTALFA (lead investor) and Pierre Fabre Medicament.